MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Schrodinger Inc

Cerrado

SectorSanidad

17.32 6.06

Resumen

Variación precio

24h

Actual

Mínimo

16.64

Máximo

17.86

Métricas clave

By Trading Economics

Ingresos

10M

-33M

Ventas

-435K

54M

Margen de beneficios

-60.369

Empleados

891

EBITDA

10M

-31M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+32.95% upside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-276M

1.2B

Apertura anterior

11.26

Cierre anterior

17.32

Noticias sobre sentimiento de mercado

By Acuity

56%

44%

308 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Schrodinger Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ene 2026, 21:55 UTC

Ganancias

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 ene 2026, 23:52 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 ene 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 ene 2026, 23:40 UTC

Charlas de Mercado

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 ene 2026, 22:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 ene 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

22 ene 2026, 21:44 UTC

Ganancias

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 ene 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 ene 2026, 21:30 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One To Acquire Brex >COF

22 ene 2026, 21:13 UTC

Ganancias

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 ene 2026, 21:10 UTC

Ganancias

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 ene 2026, 21:06 UTC

Ganancias

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Rev $15.58B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q EPS $3.26 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Interest Margin 8.26% >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net $2.13B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Adj EPS $3.86 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Charge-Offs $3.8B >COF

22 ene 2026, 21:05 UTC

Ganancias

Intuitive Surgical 4Q EPS $2.21 >ISRG

Comparación entre iguales

Cambio de precio

Schrodinger Inc previsión

Precio Objetivo

By TipRanks

32.95% repunte

Estimación a 12 Meses

Media 21.83 USD  32.95%

Máximo 25 USD

Mínimo 18 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Schrodinger Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

4

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.27 / 26.13Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Very Strong Bullish Evidence

Sentimiento

By Acuity

308 / 360 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat